Donahue group: Neuroengineering
Ismailova group: Bioelectronic textiles
Textiles offer a variety of advantages as mechanical supports for bioelectronic devices including low cost, conformability, and reduced invasiveness. We are exploring the integration of different bioelectronic devices on textiles, including electrodes, transistors and biochemical sensors. We use traditional and non-traditional patterning techniques such as photolithography and printing. The aim is to develop a family of medical devices for long-term monitoring of patients in the clinic and for applications in sports and recreation.
Moreau group: Flexible optical /electrical microelectrode array systems for infrared neural stimulation
Focused on the conception and development of a new generation of implantable neural devices, combining microelectrodes to assess neural activity with flexible waveguides to deliver infrared light with the aim of simultaneously stimulating neural activity with a better spatial resolution.
O’Connor group: Oncoelectronics
Cancer is a disease with electrical aspects that have yet to be exploited therapeutically. We are developing new ways of electrically interfacing with and controlling malignant tissue with pulsed electric fields, pursuing a device-based electroceutical approach to cancer therapeutics which we call Oncoelectronics. At the moment, we are exploring the potential of flexible organic electronic technology for the application of bioelectric therapeutics and the sensing of cancer. This fusion of bioelectronics and bioelectrics aims to develop new delivery devices for electropulsation and electroporation-related therapeutics (electrochemotherapy, electrogenetherapy, irreversible electroporation and ultrashort pulsed electric therapies). Current projects include the development of microelectrode arrays for in vitro multiwell, high throughput imaging-based screening studies of bioelectric effects on cancer, and the development of flexible organic electrode arrays for the delivery of pulsed electric fields in vivo for preclinical cancer investigations.